The BICD1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. CRISPR/Cas9-mediated disruption of the BICD1 gene generates a loss-of-function model for studying cargo adaptor functions in intracellular transport. The polyclonal population ensures diverse allelic edits, providing a comprehensive representation of gene disruption effects without clonal selection artifacts.
A-549 cells originate from a 58-year-old Caucasian male with lung carcinoma and are extensively used as an epithelial model for respiratory research and drug screening. This adherent cell line retains key characteristics of type II alveolar cells, making it suitable for investigating lung adenocarcinoma biology, tumor cell migration, and chemotherapeutic sensitivity.
BICD1 serves as a cargo adaptor linking activated RAB6A on Golgi membranes to the dynein-dynactin motor complex, enabling minus-end-directed vesicle transport. It interacts directly with DCTN1 and DYNLL1, and its activity is regulated by CDK1 kinase and COPI coat components. Downstream consequences include Golgi ribbon organization, autophagosome trafficking, and modulation of ??-catenin nuclear localization, positioning BICD1 at the interface of membrane traffic and signaling.
In A-549 cells, BICD1 knockout disrupts Golgi integrity as visualized by GM130 immunofluorescence, impairs autophagic flux measured by LC3-II accumulation, and alters secretory trafficking. These defects can enhance migratory behavior, underscoring the gene’s role in maintaining organelle homeostasis and regulating lung cancer cell dynamics.
Typical applications include immunofluorescence for Golgi markers, live-cell imaging of RAB6A vesicles, co-immunoprecipitation with dynein subunits, wound-healing migration assays, and cell viability tests with chemotherapeutics. This polyclonal knockout model thus provides a versatile platform for investigating retrograde transport, organelle organization, and therapeutic responses. For additional information, contact Ascent Research.
